HG-14-10-04

HG-14-10-04 is a potent ALK and mutant EGFR inhibitor with IC50s of 20 nM, 15.6 nM, 22.6 nM and 124.5 nM for ALK, EGFRLR/TM, EGFR19del/TM/CS and EGFRLR/TM/CS, respectively. HG-14-10-04 can be used to research anticancer[1][2].

Product Specifications

CAS Number

[1356962-34-9]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Anaplastic lymphoma kinase (ALK) ; EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/HG-14-10-04.html

Purity

99.09

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

ClC1=CN=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C=C2OC)N=C1C5=CNC6=CC=CC=C65

Molecular Formula

C29H34ClN7O

Molecular Weight

532.08

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]U.S. Pat. Appl. Publ. (2012), US 20120028924 A1|[2]Chen H, et al. Conformational Constrained 4- (1-Sulfonyl-3-indol) yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J Med Chem. 2022 May 12;65 (9) :6840-6858.